Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
J&J refutes FDA findings on asbestos in talcJohnson & Johnson has rejected an assertion by the FDA that asbestos had been found in one of Share XJ&J refutes FDA findings on asbestos in talchttps://pharmaphorum.com/news/jj-refutes-fda-findings-on-asbestos-in-talc/
The best-selling drugs of the next 5 yearsMerck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in Share XThe best-selling drugs of the next 5 yearshttps://pharmaphorum.com/views-analysis-sales-marketing/the-best-selling-drugs-of-the-next-5-years/
Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
Teva’s strategy for multichannel engagementTeva has a simple strategy for multichannel customer relationship management (CRM) and at its heart is the alignment Share XTeva’s strategy for multichannel engagementhttps://pharmaphorum.com/sales-marketing/tevas-strategy-for-multichannel-engagement/
Allergan pays $750m to avoid Alzheimer’s drug lawsuitAllergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of Share XAllergan pays $750m to avoid Alzheimer’s drug lawsuithttps://pharmaphorum.com/news/allergan-pays-750m-to-avoid-alzheimers-drug-lawsuit/
Intouch Group opens two California officesIntouch Group has announced it is further expanding its US footprint with the opening of two new offices Share XIntouch Group opens two California officeshttps://pharmaphorum.com/sales-marketing/intouch-group-opens-two-california-offices/
Artificial intelligence in pharma sales & marketing: practical opportunities for implementationThe buzz around AI can often be overwhelming, with little indication of how to separate wishful predictions from Share XArtificial intelligence in pharma sales & marketing: practical opportunities for implementationhttps://pharmaphorum.com/digital/artificial-intelligence-in-pharma-sales-marketing-practical-opportunities-for-implementation/
AZ’s new cancer drugs drive another stellar quarterAstraZeneca has raised its sales guidance of the year once again as its trio of new cancer drugs Share XAZ’s new cancer drugs drive another stellar quarterhttps://pharmaphorum.com/news/azs-new-cancer-drugs-drive-another-stellar-quarter/
